Back to top

PTC Therapeutics Sets Up Long-Term FA Study, Adding a New Catalyst for PTCT Investors

PTC Therapeutics ($PTCT) announced an update on their ongoing clinical study. PTC Therapeutics is launching a Phase 3 study called “Evaluation of L...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

PTC Therapeutics, Inc. (PTCT)